Local applications of GM-CSF induce the recruitment of immune cells in cervical low-grade squamous intraepithelial lesions

American Journal of Reproductive Immunology

Volumn 64, Issue 2, 2010, Pages 126-136

  Hubert, Pascale ^a   Doyen, Jean ^a   Capelle, Xavier ^a   Arafa, Mohammad ^a   Renoux, Virginie ^a   Bisig, Bettina ^a   Seidel, Laurence ^a   Evrard, Brigitte ^a   Bousarghin, Latifa ^a,b   Gerday, Colette ^a   Boniver, Jacques ^a   Foidart, Jean Michel ^a   Delvenne, Philippe ^a   Jacobs, Nathalie ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Clinical trial; Granulocyte macrophage colony stimulating factor; Human papillomavirus; Immune response; Safety; Uterine cervical lesion

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PLACEBO; IMMUNOLOGIC FACTOR; VIRUS ANTIBODY;

ADULT; ANTIBODY TITER; ANTIGEN PRESENTING CELL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXIC LYMPHOCYTE; DISEASE SEVERITY; DRUG TOLERABILITY; DYSPAREUNIA; FEMALE; FOLLOW UP; GENITAL PAIN; HEADACHE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; NATURAL KILLER CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; URINARY DYSFUNCTION; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX LOW GRADE SQUAMOUS INTRAEPITHELIAL LESION; WART VIRUS; ADAPTIVE IMMUNITY; BLOOD; CELL LINE; CELL PROLIFERATION; CERVICAL INTRAEPITHELIAL NEOPLASIA; COMPLICATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECTS; IMMUNOLOGY; ISOLATION AND PURIFICATION; KERATINOCYTE; LYMPHOCYTE SUBPOPULATION; MIDDLE AGED; NATURAL KILLER T CELL; NEOPLASMS, SQUAMOUS CELL; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TOPICAL DRUG ADMINISTRATION; TUMOR ASSOCIATED LEUKOCYTE; UTERINE CERVICAL NEOPLASMS; VIROLOGY; YOUNG ADULT;

ADAPTIVE IMMUNITY; ADMINISTRATION, TOPICAL; ADULT; ANTIBODIES, VIRAL; ANTIGEN-PRESENTING CELLS; CELL LINE; CELL PROLIFERATION; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOLOGIC FACTORS; KERATINOCYTES; LYMPHOCYTE SUBSETS; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; NATURAL KILLER T-CELLS; NEOPLASMS, SQUAMOUS CELL; PAPILLOMAVIRUS INFECTIONS; T-LYMPHOCYTES, CYTOTOXIC; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 77958086473     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/j.1600-0897.2010.00834.x     Document Type: Article

References (41)

1. Bosch FX: HPV vaccines and cervical cancer. Ann Oncol 2008; 19(Suppl. 5):v48-v51.
2. Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, Schiller JT, Gonzalez P, Dubin G, Porras C, Jimenez SE, Lowy DR: Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007; 298:743-753.
3. Petry KU, Scheffel D, Bode U, Gabrysiak T, Köchel H, Kupsch E, Glaubitz M, Niesert S, Kühnle H, Schedel I: Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions. Int J Cancer 1994; 57:836-840.
4. Welters MJ, de Jong A, van den Eeden SJ, van der Hulst JM, Kwappenberg KM, Hassane S, Franken KL, Drijfhout JW, Fleuren GJ, Kenter G, Melief CJ, Offringa R, van der Burg SH: Frequent display of human papillomavirus type E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res 2003; 63:636-641.
5. Scott M, Stites DP, Moscicki AB: Th1 cytokine patterns in cervical human papillomavirus infection. Clin Diagn Lab Immunol 1999; 6:751-755.
6. Samson SL, Bentley JR, Fahey TJ, McKay DJ, Gill GH: The effect of loop electrosurgical excision procedure on future pregnancy outcome. Obstet Gynecol 2005; 105:325-332.
7. Prato B, Ghelardi A, Gadducci A, Marchetti I, Di Cristofano C, Di Coscio G, Bevilacqua G, Genazzani AR: Correlation of recurrence rates and times with posttreatment human papillomavirus status in patients treated with loop electrosurgical excision procedure conization for cervical squamous intraepithelial lesions. Int J Gynecol Cancer 2008; 18:90-94.
8. Al-Saleh W, Delvenne P, Arrese Estrada JE, Nikkels AF, Pierard GE, Boniver J: Inverse modulation of intraepithelial Langerhans cells and stromal macrophage populations in human papillomavirusassociated squamous intraepithelial lesions of the cervix. Virchows Arch 1995; 427:41-48.
9. Giannini SL, Hubert P, Doyen J, Boniver J, Delvenne P: Influence of the mucosal epithelium microenvironment on Langerhans cells: implications for the development of squamous intraepithelial lesions of the cervix. Int J Cancer 2002; 97:654-659.
10. Hubert P, Evrard B, Maillard C, Franzen-Detrooz E, Delattre L, Foidart JM, Noel A, Boniver J, Delvenne P: Delivery of granulocyte-macrophage colonystimulating factor in bioadhesive hydrogel stimulates migration of dendritic cells in models of human papillomavirus-associated (pre)neoplastic epithelial lesions. Antimicrob Agents Chemother 2004; 48:4342-4348.
11. Colasante A, Castrilli G, Aiello FB, Brunetti M, Musiani P: Role of cytokines in distribution and differentiation of dendritic cell/Langerhans' cell lineage in human primary carcinomas of the lung. Hum Pathol 1995; 26:866-872.
12. Hubert P, Giannini SL, Vanderplasschen A, Franzen-Detrooz E, Jacobs N, Boniver J, Delvenne P: Dendritic cells induce the death of human papillomavirus-transformed keratinocytes. FASEB J 2001; 15:2521-2523.
13. Manna PP, Mohanakumar T: Human dendritic cell mediated cytotoxicity against breast carcinoma cells in vitro. J Leukoc Biol 2002; 72:312-320.
14. Verra N, Jansen R, Groenewegen G, Mallo H, Kersten MJ, Bex A, Vyth-Dreese FA, Sein J, van de Kasteele W, Nooijen WJ, de Waal M, Horenblas S, de Gast GC: Immunotherapy with concurrent subcutaneous GMCSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma. Br J Cancer 2003; 88:1346-1351.
15. Baur M, Schernhammer E, Gneist M, Sevelda P, Speiser P, Hudec M, Dittrich C: Phase I/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer. Br J Cancer 2005; 92:1019-1025.
16. Chianese-Bullock KA, Irvin WP Jr, Petroni GR, Murphy C, Smolkin M, Olson WC, Coleman E, Boerner SA, Nail CJ, Neese PY, Yuan A, Hogan KT, Slingluff CL Jr: A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. J Immunother 2008; 31:420-430.
17. Dalstein V, Merlin S, Bali C, Saunier M, Dachez R, Ronsin C: Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus. J Virol Methods 2009;456: 77-83.
18. Hubert P, Caberg JH, Gilles C, Bousarghin L, Franzen-Detrooz E, Boniver J, Delvenne P: E-cadherindependent adhesion of dendritic and Langerhans cells to keratinocytes is defective in cervical human papillomavirus-associated (pre)neoplastic lesions. J Pathol 2005; 206:346-355.
19. Hallez S, Simon P, Maudoux F, Doyen J, Noel JC, Beliard A, Capelle X, Buxant F, Fayt I, Lagrost A-C, Hubert P, Gerday C, Burny A, Boniver J, Foidart J-M, Delvenne P, Jacobs N: Phase I/II immunogenicity of a Human Papillomavirus (HPV) type 16 E7 proteinbased vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Cancer Immunol Immunother 2004; 53:642-650.
20. Combita AL, Touze A, Bousarghin L, Sizaret PY, Munoz N, Coursaget P: Gene transfer using human papillomavirus pseudovirions varies according to virus genotype and requires cell surface heparan sulfate. FEMS Microbiol Lett 2001; 204:183-188.
21. Combita AL, Bravo MM, Touze A, Orozco O, Coursaget P: Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39 58, and virus-like particles in colombian women with invasive cervical cancer. Int J Cancer 2002; 97:796-803.
22. Gutschalk CM, Herold-Mende CC, Fusenig NE, Mueller MM: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor promote malignant growth of cells from head and neck squamous cell carcinomas in vivo. Cancer Res 2006; 66:8026-8036.
23. Al-Saleh W, Delvenne P, Greimers R, Fridman V, Doyen J, Boniver J: Assessment of Ki-67 antigen immunostaining in squamous intraepithelial lesions of the uterine cervix. Correlation with the histologic grade and human papillomavirus type. Am J Clin Pathol 1995; 104:154-160.
24. Castellsague X, de Sanjose S, Aguado T, Louie KS, Bruni L, Munoz J, Diaz K, Gacic M, Beauvais O, Albero G, Ferrer E, Byrne S, Bosch FX: HPV and cervical cancer in the World 20report. Vaccine 2007; 25:C1-C1229.
25. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM: A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007; 195:1582-1589.
26. Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti MC, Sherman ME, Wacholder S, Tarone R, Burk RD: A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005; 191:1808-1816.
27. Stanley MA: Mechanism of action of Imiquimod. Papillomavirus Rep 1999; 10:23-29.
28. Garland SM: Imiquimod. Curr Opin Infect Dis 2003; 16:85-89.
29. Gilson RJ, Shupack JL, Friedman-Kien AE, Conant MA, Weber JN, Nayagam AT, Swann RV, Pietig DC, Smith MH, Owens ML: A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. Imiquimod Study Group. AIDS 1999; 13:2397-2404.
30. Wagstaff AJ, Perry CM: Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions. Drugs 2007; 67:2187-2210.
31. van Seters M, van Beurden M, ten Kate FJ, Beckmann I, Ewing PC, Eijkemans MJ, Kagie MJ, Meijer CJ, Aaronson NK, Kleinjan A, Heijmans-Antonissen C, Zijlstra FJ, Burger MP, Helmerhorst TJ: Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Eng J Med 2008; 358:1465-1473.
32. Hubert P, Herman L, Maillard C, Caberg JH, Nikkels A, Pierard G, Foidart JM, Noel A, Boniver J, Delvenne P: Defensins induce the recruitment of dendritic cells in cervical human papillomavirusassociated (pre)neoplastic lesions formed in vitro and transplanted in vivo. FASEB J 2007; 21:2765-2775.
33. Davidson EJ, Boswell CM, Sehr P, Pawlita M, Tomlinson AE, McVey RJ, Dobson J, Roberts JS, Hickling J, Kitchener HC, Stern PL: Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res 2003; 63:6032-6041.
34. Simmons AD, Li B, Gonzalez-Edick M, Lin C, Moskalenko M, Du T, Creson J, VanRoey MJ, Jooss K: GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action. Cancer Immunol Immunother 2007; 56:1653-1665.
35. Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S, Tanabe K, Duda R, Mentzer S, Jaklitsch M, Bueno R, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Mihm M, Dranoff G: Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003; 21:3343-3350.
36. Textor S, Durst M, Jansen L, Accardi R, Tommasino M, Trunk MJ, Porgador A, Watzl C, Gissmann L, Cerwenka A: Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer. Int J Cancer 2008; 123:2343-2353.
37. Chang EY, Chen CH, Ji H, Wang TL, Hung K, Lee BP, Huang AY, Kurman RJ, Pardoll DM, Wu T: Antigenspecific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine. Int J Cancer 2000; 86:725-730.
38. Nakagawa M, Stites DP, Patel S, Farhat S, Scott M, Hills NK, Palefsky JM, Moscicki AB: Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. J Infect Dis 2000; 182:595-598.
39. Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Lowik MJ, Berends-van der Meer DM, Drijfhout JW, Valentijn AR, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, Melief CJ, van der Burg SH: Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type E6 and E7 long peptides vaccine. Clin Cancer Res 2008; 14:178-187.
40. Zou W: Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6:295-307.
41. Pinto LA, Viscidi R, Harro CD, Kemp TJ, Garcia-Pineres AJ, Trivett M, Demuth F, Lowy DR, Schiller JT, Berzofsky JA, Hildesheim A: Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-L1 virus-like particles. Virology 2006; 353:451-462.